CNS Pharma · IPO underway

Title

Entry must be under 140 characters.

Dear Investors,At long last our IPO process is underway. You may have received information from one of our investment banks regarding the opportunity to participate in the IPO.  The Benchmark Company, LLC will act as the sole underwriter for the proposed offering. The public offering will be made only by means of a prospectus, which may be obtained by writing or calling James Bernthal, Senior Vice President - Investments, Dawson James Securities, Inc. 530 5th Ave. 21st Floor New York, NY 10036(855) 928-0929 – Toll Free (212) 897-9912 – Main (646) 465-6892 – Direct <a href="mailto:jbernthal@dawsonjames.com" rel="nofollow">jbernthal@dawsonjames.com</a>A registration statement relating to the proposed sale of these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Cancel

Oct 22

2019

IPO underway

Dear Investors,

At long last our IPO process is underway. You may have received information from one of our investment banks regarding the opportunity to participate in the IPO. The Benchmark Company, LLC will act as the sole underwriter for the proposed offering. The public offering will be made only by means of a prospectus, which may be obtained by writing or calling James Bernthal, Senior Vice President - Investments, Dawson James Securities, Inc. 530 5^th Ave. 21^st Floor New York, NY 10036

(855) 928-0929 – Toll Free
(212) 897-9912 – Main
(646) 465-6892 – Direct

jbernthal@dawsonjames.com

A registration statement relating to the proposed sale of these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

IPO underway

Open for investment

Rentberry

Code Blue

Mintworks